1. Home
  2. NRXS vs SPWRW Comparison

NRXS vs SPWRW Comparison

Compare NRXS & SPWRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRXS
  • SPWRW
  • Stock Information
  • Founded
  • NRXS 2011
  • SPWRW N/A
  • Country
  • NRXS United States
  • SPWRW United States
  • Employees
  • NRXS N/A
  • SPWRW N/A
  • Industry
  • NRXS
  • SPWRW Semiconductors
  • Sector
  • NRXS
  • SPWRW Technology
  • Exchange
  • NRXS Nasdaq
  • SPWRW Nasdaq
  • Market Cap
  • NRXS 13.0M
  • SPWRW 15.5M
  • IPO Year
  • NRXS 2023
  • SPWRW N/A
  • Fundamental
  • Price
  • NRXS $2.60
  • SPWRW $0.23
  • Analyst Decision
  • NRXS
  • SPWRW
  • Analyst Count
  • NRXS 0
  • SPWRW 0
  • Target Price
  • NRXS N/A
  • SPWRW N/A
  • AVG Volume (30 Days)
  • NRXS 4.9M
  • SPWRW N/A
  • Earning Date
  • NRXS 05-12-2025
  • SPWRW N/A
  • Dividend Yield
  • NRXS N/A
  • SPWRW N/A
  • EPS Growth
  • NRXS N/A
  • SPWRW N/A
  • EPS
  • NRXS N/A
  • SPWRW N/A
  • Revenue
  • NRXS $2,934,945.00
  • SPWRW N/A
  • Revenue This Year
  • NRXS $138,883.78
  • SPWRW N/A
  • Revenue Next Year
  • NRXS $118.59
  • SPWRW N/A
  • P/E Ratio
  • NRXS N/A
  • SPWRW N/A
  • Revenue Growth
  • NRXS 27.52
  • SPWRW N/A
  • 52 Week Low
  • NRXS $1.33
  • SPWRW N/A
  • 52 Week High
  • NRXS $6.20
  • SPWRW N/A
  • Technical
  • Relative Strength Index (RSI)
  • NRXS 50.26
  • SPWRW N/A
  • Support Level
  • NRXS $2.59
  • SPWRW N/A
  • Resistance Level
  • NRXS $2.82
  • SPWRW N/A
  • Average True Range (ATR)
  • NRXS 0.46
  • SPWRW 0.00
  • MACD
  • NRXS -0.04
  • SPWRW 0.00
  • Stochastic Oscillator
  • NRXS 12.83
  • SPWRW 0.00

About NRXS Neuraxis Inc.

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Share on Social Networks: